London-based preclinical biopharmaceutical firm TOKYO Pharma Limited has made significant strides in the development of therapeutics targeted at managing and treating inflammatory eye diseases and ocular pain. The company's flagship preclinical product, OK-101, has demonstrated significant potential in clinical trials as a treatment for dry eye disease. Additionally, TOKYO Pharma Limited is pioneering the development of OK-201, a novel peptide analog derived from bovine adrenal medulla with promising applications in the treatment of neuropathic ocular pain. Founded in 2007, TOKYO Pharma Limited continues to operate at the forefront of innovative biopharmaceutical solutions and is poised to become a major player in the field of ocular therapeutics.
OKYO Pharma Limited's ticker is OKYO
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 1-10 employees working at OKYO Pharma Limited
It is https://www.okyopharma.com/
OKYO Pharma Limited is in the Healthcare sector
OKYO Pharma Limited is in the Biotechnology industry
The following five companies are OKYO Pharma Limited's industry peers: